aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to become a global leader in immune-based therapies, Zenas BioPharma operates as a cross-border biopharmaceutical company between China and the USA. The company focuses on developing and delivering innovative therapeutics for immune-related diseases, aiming to improve patient outcomes worldwide. Zenas BioPharma's pipeline includes a range of advanced therapeutics designed to address unmet medical needs, positioning itself at the forefront of biopharmaceutical innovation.
Notable figures affiliated with Zenas BioPharma include experienced industry leaders and scientists who drive the company's research and development efforts. The company has attracted significant investment from prominent venture capital firms, underscoring its potential in the biopharmaceutical sector. Key achievements include the rapid advancement of its therapeutic pipeline and strategic partnerships that enhance its global reach. Zenas BioPharma's impact is marked by its commitment to bringing cutting-edge treatments to patients, thereby contributing to the global healthcare landscape.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Immune Therapies
Technology
Biotech
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Zenas BioPharma founded?
Zenas BioPharma was founded in 2020.
Where is Zenas BioPharma's headquarters located?
Zenas BioPharma's headquarters is located in Waltham, MA, US.
When was Zenas BioPharma's last funding round?
Zenas BioPharma's most recent funding round was for $118M (USD) in November 2022.
How many employees does Zenas BioPharma have?
Zenas BioPharma has 70 employees as of Feb 4, 2024.
How much has Zenas BioPharma raised to-date?
As of July 05, 2023, Zenas BioPharma has raised a total of $118M (USD) since Nov 7, 2022.
Add Comparison
Total Raised to Date
$118M
USD
Last Update Nov 7, 2022
Last Deal Details
$118M
USD
Nov 7, 2022
Series B
Total Employees Over Time
70
As of Feb 2024
Zenas BioPharma Address
1000 Winter St
Suite 1200
Waltham,
Massachusetts
02451
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts